FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozapine
FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozap...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- FDA Drug Approvals
- Region
- USA
- Scope
- Regulatory
- Published
- April 4, 2026
- Language
- EN
Topics
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozap...
Source route
Continue on fda.gov
Leave the platform to read the original full article on the publisher site.
Source: FDA Drug Approvals
Scope: Regulatory
Related coverage